Organon Q3 Earnings Beat Estimates With $164 Million Profit, Revenue of $1.57 Billion

Organon & Co. (OGN) reported third-quarter earnings of $164 million, or 60 cents per share, surpassing Wall Street expectations, the Jersey City, New Jersey-based pharmaceutical company said Friday. Adjusted for non-recurring costs and stock option expense, earnings came to 94 cents per share, exceeding the average estimate of 91 cents per share from three analysts surveyed by Zacks Investment Research. The company posted revenue of $1.57 billion for the period.